Thursday Mar 13
Are We Ignoring The Counter View On Five Prime?
Five Prime Therapeutics started trading as a listed company on September 18, 2013 after raising $62 million through an IPO of 4.8 million shares at $13 a share.
Inside Bay Area
Apotex must face Genentech patent claim over Valcyte generic
Apotex must face a Roche Holding lawsuit claiming its generic version of Valcyte, which treats a virus that afflicts transplant patients and people with AIDS, infringes a Roche patent that expires in 2015.
Five Prime Therapeutics to Present at 26th Annual Roth Conference
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer of Five Prime, will present at the 26th Annual Roth Conference on Tuesday, March 11 at 5:30 p.m. Pacific Time.
Wall Street Journal
New Roche Chief Plans No Big Changes
Christoph Franz, the new chairman of Roche Holding AG, said the Swiss pharmaceutical giant needs to continue focusing on innovation but he plans no major changes as he takes the helm of the company.
The Washington Post
Roche May Share Trial Data Amid Brain Cancer Conflict
Roche Holding AG and a group of outside investigators may share raw data from conflicting trials of Avastin to help determine whether the $7 billion-a-year treatment really helps patients with deadly brain cancer.